Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes Insulin, Sulfonylureas Raise Cardiovascular Risk in Diabetes
Real-world data also show no cardiovascular harm from newer glucose-lowering agents, but less benefit than was seen in randomized trials of patients with type 2 diabetes and established CVD.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Insulin